Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1228 | Digital cardiac Counseling Wiki | 1.00 |
| drug1047 | Convalescent Plasma Wiki | 0.19 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001626 | Abnormality of the cardiovascular system HPO | 0.17 |
Navigate: Correlations HPO
There is one clinical trial.
The purpose of this study is to determine if treatment with convalescent plasma improves the clinical outcomes of Veterans who are hospitalized and require supplemental oxygen due to COVID-19.
Description: Respiratory failure is defined by requiring mechanical ventilation, with or without endotracheal intubations, or extra-corporeal membrane oxygenation.
Measure: Proportion of participants developing acute hypoxemic respiratory failure or all-cause death Time: Day 1 through Day 28Description: Day of recovery is defined as the first day on which the subject satisfies one of the following three categories from the ordinal scale: 1) Not hospitalized, no limitations on activities; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen and no longer requires ongoing medical care.
Measure: Time (in days) to recovery Time: Day 1 through Day 28Description: Defined as the first day on which the subject died from any cause or had respiratory failure. Respiratory failure is defined by requiring mechanical ventilation, with or without endotracheal intubations, or extra-corporeal membrane oxygenation.
Measure: Time (in days) to death or respiratory failure Time: Day 1 through Day 28Description: Defined as the proportion of subjects who died from any cause or had respiratory failure, or who required humidified heater high-flow cannula (HHHFNC). Respiratory failure is defined by requiring mechanical ventilation, with or without endotracheal intubations, or extra-corporeal membrane oxygenation.
Measure: Proportion of patients who died from any cause, had respiratory failure, or required humidified heated high-flow nasal cannula (HHHFNC) at 15 Lpm Time: Day 1 through Day 28Description: Time to death or respiratory failure is defined as the first day on which the subject died from any cause or had respiratory failure (defined above), or who required HHHFNC at 15 Lpm.
Measure: Time (in days) to death or respiratory failure or HHHFNC at 15 Lpm Time: Day 1 through Day 28Description: Date and cause of death (if applicable)
Measure: Subject 28-day all-cause mortality Time: Day 1 through Day 28Description: Modified WHO 8-point Ordinal Scale for Clinical Improvement. The scale is as follows: 0) No clinical or Virologic evidence of infection; 1) No limitation of activity; 2) Limitation of activity and/or home oxygen; 3) Hospitalized, no oxygen therapy; 4) Oxygen by mask or nasal prong; 5a) Humidified high-flow oxygen; 5b) Non-invasive ventilation; 6) Intubation and mechanical Ventilation; 7) Ventilation + additional organ support-pressors, RRT, ECMO; 8) Death. The higher the score, the worse the outcome.
Measure: Time to an improvement of one category using an ordinal scale Time: Up through 28 days.Description: Modified WHO 8-point Ordinal Scale for Clinical Improvement. The scale is as follows: 0) No clinical or Virologic evidence of infection; 1) No limitation of activity; 2) Limitation of activity and/or home oxygen; 3) Hospitalized, no oxygen therapy; 4) Oxygen by mask or nasal prong; 5a) Humidified high-flow oxygen; 5b) Non-invasive ventilation; 6) Intubation and mechanical Ventilation; 7) Ventilation + additional organ support-pressors, RRT, ECMO; 8) Death. The higher the score, the worse the outcome.
Measure: Time to an improvement of two categories using an ordinal scale Time: Up through 28 days.Description: Modified WHO 8-point Ordinal Scale for Clinical Improvement. The scale is as follows: 0) No clinical or Virologic evidence of infection; 1) No limitation of activity; 2) Limitation of activity and/or home oxygen; 3) Hospitalized, no oxygen therapy; 4) Oxygen by mask or nasal prong; 5a) Humidified high-flow oxygen; 5b) Non-invasive ventilation; 6) Intubation and mechanical Ventilation; 7) Ventilation + additional organ support-pressors, RRT, ECMO; 8) Death. The higher the score, the worse the outcome.
Measure: Participant's clinical status by ordinal scale Time: Up through 28 days.Description: Modified WHO 8-point Ordinal Scale for Clinical Improvement. The scale is as follows: 0) No clinical or Virologic evidence of infection; 1) No limitation of activity; 2) Limitation of activity and/or home oxygen; 3) Hospitalized, no oxygen therapy; 4) Oxygen by mask or nasal prong; 5a) Humidified high-flow oxygen; 5b) Non-invasive ventilation; 6) Intubation and mechanical Ventilation; 7) Ventilation + additional organ support-pressors, RRT, ECMO; 8) Death. The higher the score, the worse the outcome.
Measure: Mean change in the ordinal scale Time: Days 2, 4, 7, 11, 14, 21, and 28.Description: The NEWS2 score has demonstrated an ability to discriminate patients at risk of poor outcomes. This score is based on 7 clinical parameters. The NEW Score-2 is being used as an efficacy measure.
Measure: Time to discharge or to a National Early Warning Score (NEWS)-2 of = 2 and maintained for 24 hours, whichever occurs first Time: Up through 28 days.Description: The NEWS2 score has demonstrated an ability to discriminate patients at risk of poor outcomes. This score is based on 7 clinical parameters. The NEW Score-2 is being used as an efficacy measure.
Measure: Change in NEWS-2 Score from Day 1 (baseline) to Days 2, 4, 7, 11, 15, and 29 Time: From Day 1 (baseline) to Days 2, 4, 7, 11, 15, and 29Description: Measured in days.
Measure: Duration of hospitalization Time: Day 1 through Day 28Description: Measured in days.
Measure: Number of hospitalizations related to COVID-19 Time: Day 1 through Day 28Description: An SAE is defined as an AE or suspected adverse reaction is considered serious if, in the view of either the investigator or the sponsor, it results in death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect.
Measure: Cumulative incidence of Serious Adverse Events (SAEs) Time: Day 1 through Day 29Description: Grade 3 AEs are defined as events that interrupt usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention. Severe events are usually incapacitating. Grade 4 AEs are defined as events that are potentially life threatening.
Measure: Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs) Time: Day 1 through Day 29Description: Incidence of occurrence.
Measure: Incidence of discontinuation or temporary suspension of study product administrations (for any reason) Time: Day 1 through Day 29Description: g/dL
Measure: Change from baseline in hemoglobin Time: Day 1 to Days 2, 4, and 7 (while hospitalized); and Days 15 and 29 (if attends in-person visit or still hospitalized).Description: K/mcL
Measure: Change from baseline in platelets Time: Day 1 to Days 2, 4, and 7 (while hospitalized); and Days 15 and 29 (if attends in-person visit or still hospitalized).Description: mm/L
Measure: Change from baseline in creatinine Time: Day 1 to Days 2, 4, and 7 (while hospitalized); and Days 15 and 29 (if attends in-person visit or still hospitalized).Description: mg/dL
Measure: Change from baseline in glucose Time: Day 1 to Days 2, 4, and 7 (while hospitalized); and Days 15 and 29 (if attends in-person visit or still hospitalized).Description: mg/dL
Measure: Change from baseline in total bilirubin Time: Day 1 to Days 2, 4, and 7 (while hospitalized); and Days 15 and 29 (if attends in-person visit or still hospitalized).Description: U/L
Measure: Change from baseline in alanine transaminase (ALT) Time: Day 1 to Days 2, 4, and 7 (while hospitalized); and Days 15 and 29 (if attends in-person visit or still hospitalized).Description: U/L
Measure: Change from baseline in aspartate transaminase (AST) Time: Day 1 to Days 2, 4, and 7 (while hospitalized); and Days 15 and 29 (if attends in-person visit or still hospitalized).Description: PT reported as international normalized ratio (INR).
Measure: Change from baseline in prothrombin time (PT) Time: Day 1 to Days 2, 4, and 7 (while hospitalized); and Days 15 and 29 (if attends in-person visit or still hospitalized).Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports